The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
Open accessAbstract
The development of anti-drug antibodies (ADAs) following administration of biotherapeutics to patients is a vexing problem that is attracting increasing attention from pharmaceutical and biotechnology companies. This serious clinical problem is also spawning creative research into novel approaches to predict, avoid, and in some cases even reverse such deleterious immune responses. CD4+ T cells are essential players in the development of most ADAs, while memory B-cell and long-lived plasma cells amplify and maintain these responses. This review summarizes methods to predict and experimentally identify T-cell and B-cell epitopes in therapeutic proteins, with a particular focus on blood coagulation factor VIII (FVIII), whose immunogenicity is clinically significant and is the subject of intensive current research. Methods to phenotype ADA responses in humans are described, including T-cell stimulation assays, and both established and novel approaches to determine the titers, epitopes and isotypes of the ADAs themselves. Although rational protein engineering can reduce the immunogenicity of many biotherapeutics, complementary, novel approaches to induce specific tolerance, especially during initial exposures, are expected to play significant roles in future efforts to reduce or reverse these unwanted immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Surface plasmon resonance (SPR)-based epitope mapping. (A). Representative superimposed sensorgrams showing single-cycle kinetics experiments in which rFVIII-C2 protein and rFVIII-C2 variants with a single surface-exposed side chain mutated to alanine were injected at increasing concentrations over a FVIII-specific MAb captured on a biosensor [97]. Residues were flagged as potential contributors to the epitope if the kd for the FVIII-C2 mutein was >2.0X the kd for the wild-type rFVIII-C2 protein. Alanine substitutions at residues E2228, L2252, S2254, H2315 and Q2316 met this criterion in this set of experiments with MAb 1B5. Separate SPR runs (not shown here) identified residues F2196, T2197, N2198, F2200, T2202, R2220, Q2222, N2225 and K2239 as also possibly contributing to the epitope recognized by this MAb. (B). Front and back views (rotated 180°) of the FVIII C2 domain crystal structure [100], with surfaces colored to indicate the 5 partially-overlapping B-cell epitopes recognized by 11 neutralizing MAbs. The MAbs and their cognate epitopes were designated Types A, AB, B, BC and C on the basis of competition ELISA experiments. These MAbs inhibit distinct binding interactions and functions of FVIII, e.g., binding to negatively charged phospholipid surfaces, von Willebrand factor, and other proteins comprising the ‘intrinsic tenase’ complex [88]. Type A: red; Type AB: orange; Type B: yellow; Type BC: green; Type C: blue.](https://figures.cochat.ai/paper-figures/b4e508965e1343178ea7e0a607aac94f/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-1.jpg)
![Figure 2 “Saturation SPR” method to characterize polyclonal anti-FVIII anti-drug antibodies (ADAs) in patient plasma samples [114]. First a high-affinity MAb specific for the FVIII A1 domain is covalently immobilized on the biosensor surface, and FVIII protein is then injected and captured by this MAb (0–700 s, not shown in figure). A plasma sample (pre-treated with caprylic acid to minimize biosensor fouling) is injected next (black arrows) followed by sequential injections of anti-hu IgG1, IgG2, IgG3 and IgG4 MAbs (red arrows), all at saturating concentrations. The vertical displacements (in RUs) may be converted to total mass at the biosensor surface following each injection, which is then converted to the total bound antibody concentration assuming an average molecular weight of 150 kDa. (A–F): The red and blue sensorgram curves depict matched plasma samples pre-incubated with (red) and without (blue) saturating (1 µM) recombinant FVIII-C2 domain protein, which will compete with the polyclonal anti-FVIII-C2 antibodies in the plasma samples. Thus, these paired SPR experiments indicate the total anti-FVIII polyclonal antibody titer, the fractions of IgG1, IgG2, IgG3 and IgG4 in the samples, and the fraction of antibodies specific for the FVIII C2 domain. Panels A-E illustrate the diverse phenotypes of the anti-FVIII IgG response in patients with allo-or autoimmune anti-FVIII antibodies. Panel F is a control experiment in which a patient-derived IgG4 monoclonal antibody specific for the FVIII C2 domain is tested in the same assay. No patient samples contained FVIII-specific IgM or IgGA (not shown). (G) The biosensor assay format is shown schematically, with the FVIII crystal structure [116] in ribbon representation.](https://figures.cochat.ai/paper-figures/bddf0305c399452d842a643eeb770d03/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In many cases antibodies recognize the GalNAc moiety or otherwise non-neutralizing epitopes; in-vitro neutralization does not necessarily predict in-vivo functional loss.”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The siRNA delivery platform eliminates the chance of immune responses which affect protein-based medications because no anti-drug antibodies (ADAs) developed in trial participants [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, immature dendritic cells (iDCs) are antigen presenting cells (APCs) that often present self-antigens without stimulating T cell responses, which may allow for tolerance of peptide sequences that could be harnessed in biotherapeutic treatments.143–145”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistent LDL-C suppression among antibody-positive individuals suggests limited clinical impact of the detected antibodies [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredIn the citing paper
“modulating CD4+ T cell and B cell responses may assist in reducing ADAs.144”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983 · cited 1×
“In 1995, Clackson and Wells described “hot spots” within larger protein-protein binding interfaces that contribute most of the binding affinity [101].”
BackgroundCetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Sequence analysis of peptides bound to MHC class II molecules
Rudensky, A. Y., Preston-Hurlburt, P., Hong, S.-C., Barlow, A., & Janeway, C. A. (1991) · Nature · doi:10.1038/353622a0 · Cited by 1,075 · cited 1×
“A subset of these peptides may then be presented on an individual’s Major Histocompatability Complex (MHC), restricted to their HLA Class I and/or Class II alleles [25,26].”
BackgroundProPred: prediction of HLA-DR binding sites
Singh, H., & Raghava, G. P. S. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1236 · Cited by 841
Fundamentals and Methods for T- and B-Cell Epitope Prediction
Sanchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/2680160 · Cited by 674 · cited 1×
“, peptide array or phage-display results, into epitope identification approaches greatly improves success rates, compared to ab initio methods based on amino acid sequence propensities to form beta turns, or machine-learning based algorithms [42].”
Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M., & Sette, A. (1992) · Science · doi:10.1126/science.1319610 · Cited by 646
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
Abshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Structure of the C2 domain of human factor VIII at 1.5 Å resolution
Pratt, K. P., Shen, B. W., Takeshima, K., Davie, E. W., Fujikawa, K., & Stoddard, B. L. (1999) · Nature · doi:10.1038/46601 · Cited by 308
Self-citation
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Jarantow, S. W., Pisors, E. D., & Chiu, M. L. (2023) · Current Protocols · doi:10.1002/cpz1.801 · Cited by 161
“Immunogenicity assessments such as anti-drug antibody assays (Adan et al. 2016) detect immune responses against a therapeutic, which can be immunogenic and/or neutralizing, and significantly affect PK/PD behavior (Pratt, 2018; Song et al., 2016).”
BackgroundImmunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 122
“For example, a substantial proportion of patients with haemophilia A develop neutralizing ADAs — ‘inhibitors’ in the lexicon of haematolo-gists — when treated with replacement clotting factors 45 .”
Assessing developability early in the discovery process for novel biologics
Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 108
Metadata
- Authors
- Pratt, K. P.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Corresponding author
- Pratt, Kathleen P.
- ORCID
- Pratt, Kathleen P.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2018-05-31
- Volume
- 7
- Issue
- 2
- Pages
- 19
- ISSN
- 2073-4468 (ISSN-L)
- PMC
- PMC6698869
- OpenAlex
- W2806365218
- Cited by
- 96
- References
- 149
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 19 · 2019: 5 · 2018: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (1R01 HL 130448)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- anti-drug antibodies, CD4+ T cells, memory B cells, long-lived plasma cells, epitope prediction, rational protein design, immune tolerance induction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity. https://app.cochat.ai/papers/10.3390/antib7020019
- The paper
- Pratt, K. P. (2018). Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity. Antibodies. https://doi.org/10.3390/antib7020019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.